RCS - Creo Medical Group - Welsh Labour Leader visits Creo’s facilities

Creo MedicalAnnouncement

19/03/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240319:nRSS3187Ha&default-theme=true

RNS Number : 3187H  Creo Medical Group PLC  19 March 2024

Creo Medical Group plc

("Creo" the "Company" or the "Group")

 

Welsh Labour Leader visits Creo's design and manufacturing facilities in
Chepstow

 

Creo Medical Group plc (AIM: CREO), the Chepstow based medical device company
focused on the emerging field of minimally invasive surgical endoscopy for
pre-cancer and cancer patients, was pleased to welcome Vaughan Gething MS, the
Welsh Labour leader and colleagues, to its design and manufacturing facilities
in Chepstow, Wales on Monday 18 March 2024.

 

During the visit Creo was able to showcase its pioneering endoscopic surgical
solutions, which introduce advanced energy to endoscopy in new markets and
procedures, facilitating an array of benefits to patients, clinicians and
healthcare providers. Creo is an Innovation-led Welsh company, rolling out
cutting-edge medical technology that utilises high-frequency microwave energy
and dynamic matching techniques for cancer treatment. Creo's technology can be
used to treat Bowel, Oesophagus, Stomach, Lung, Pancreas, Liver cancer, whilst
reducing waiting times and hospital backlog at a lower cost than traditional
surgical procedures and treatments.

 

Vaughan Gething, who is set to be confirmed as the First Minister of Wales
later this week, visited the site in his capacity as Leader of the Welsh
Labour Party, along with Jo Stevens, MP for Cardiff Central; Shadow Secretary
of State for Wales; and Catherine Fookes, Labour parliamentary candidate for
Monmouthshire. Vaughan Gething previously visited Creo Medical's Chepstow
Headquarters in his capacity as Economy Minister in 2023.

 

The presentation delivered at yesterday's meeting is available to view here:

https://www.creomedical.com/en/investors/reports-and-presentations
(https://www.creomedical.com/en/investors/reports-and-presentations)

 

The Welsh Government provided support to the business via its Economy Futures
Fund, to create 85 jobs while expanding its premises and investing in
state-of-the-art manufacturing equipment.

 

The Development Bank of Wales have also been strong supporters of the business
and remains a significant shareholder of the Company. Creo has also received
considerable support from local Angel Investors and UK Institutional
Investors. These investments have allowed Creo to grow its workforce, creating
well paid jobs in Chepstow.

 

Craig Gulliford, Chief Executive Officer of Creo, commented: "Creo is a great
example of a dynamic Welsh business at the very forefront of Medtech device
innovation, developing pioneering surgical devices that are being rolled out
globally, and transforming the way in which cancer can be treated. We welcome
the Welsh Government's continued support for our business and have been
delighted to demonstrate to the Welsh Labour Party leader, The Shadow
Secretary of State for Wales, and colleagues, the exciting opportunity we have
as a Welsh business to become a world-leader in this emerging field of
endoscopic surgery."

 

Shadow Secretary of State for Wales, Jo Stevens MP said: "Creo Medical is a
fantastic example of how the Welsh Labour government is backing home-grown
businesses to create well paid, skilled jobs.

 

"Their ground-breaking medtech innovations transform the surgical experience
for clinicians and patients. Welsh Government support has allowed them to grow
their business creating new, well-paid jobs here in Wales.

 

"With a Labour government at both ends of the M4, we will get our economy
growing and modernise our NHS."

 

Enquiries:

 

 Creo Medical Group plc                             www.creomedical.com (http://www.creomedical.com)
 Richard Rees (CFO)                                 +44 (0)1291 606 005

 Cavendish Capital Markets Limited                  +44 (0)20 7397 8900
 Stephen Keys / Camilla Hume (NOMAD)
 Michael Johnson (Sales)

 Deutsche Numis (Joint Broker)                      +44 (0)20 7260 1000

 Freddie Barnfield / Duncan Monteith / Euan Brown

 Walbrook PR                                        Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com
 Paul McManus / Sam Allen                           Mob: +44 (0)7980 541 893 / +44 (0)7502 558 258

 Phillip Marriage                                   +44 (0)7867 984 082

 

 

About Creo Medical

Creo Medical is a medical device company focused on the development and
commercialisation of minimally invasive electrosurgical devices, bringing
advanced energy to endoscopy.

 

The Company's vision is to improve patient outcomes through the development
and commercialisation of a suite of electrosurgical medical devices, each
enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA
powered by Kamaptive full-spectrum adaptive technology to optimise surgical
capability and patient outcomes. Kamaptive is a seamless, intuitive
integration of multi-modal energy sources, optimised to dynamically adapt to
patient tissue during procedures such as resection, dissection, coagulation
and ablation of tissue. Kamaptive technology provides clinicians with
increased flexibility, precision and controlled surgical solutions. CROMA
currently delivers bipolar radiofrequency ("RF") energy for precise localised
cutting and focused high frequency microwave ("MW") energy for controlled
coagulation and ablation via a single accessory port. This technology,
combined with the Group's range of patented electrosurgical devices, is
designed to provide clinicians with flexible, accurate and controlled clinical
solutions. The Directors believe the Company's technology can impact the
landscape of surgery and endoscopy by providing a safer, less-invasive and
more cost-efficient option for procedures.

 

For more information, please refer to the website www.creomedical.com
(http://www.creomedical.com)

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRASFSFUAELSEFD